Europese Unie - Deens - EMA (European Medicines Agency)

takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.

Europese Unie - Deens - EMA (European Medicines Agency)

takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.

Europese Unie - Deens - EMA (European Medicines Agency)

takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.

Europese Unie - Deens - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Europese Unie - Deens - EMA (European Medicines Agency)

zoetis belgium sa - maropitant citrat - alimentary tract and metabolism - dogs; cats - tabletter hunde: til forebyggelse af kvalme induceret ved kemoterapi. til forebyggelse af opkast induceret af motion sygdom. til forebyggelse og behandling af opkastning i forbindelse med cerenia injektionsvæske, opløsning og i kombination med andre understøttende foranstaltninger. løsning til injectiondogs:til behandling og forebyggelse af kvalme, der er fremkaldt af kemoterapi. til forebyggelse af opkastning bortset fra det, der induceres af motionssygdom. til behandling af opkastning, i kombination med andre understøttende foranstaltninger. til forebyggelse af perioperative kvalme og opkastning og forbedring i nyttiggørelse af generel anæstesi efter brug af μ-opioid receptor agonist morfin. katte: til forebyggelse af opkastning og reduktion af kvalme, bortset fra det, der fremkaldes af bevægelsessyge. til behandling af opkastning, i kombination med andre understøttende foranstaltninger.

Europese Unie - Deens - EMA (European Medicines Agency)

forte healthcare limited - fluoxetin - psychoanaleptics - hunde - som hjælp til behandling af separationsrelaterede lidelser hos hunde manifesteret ved ødelæggelse og uhensigtsmæssig adfærd (vokalisering og uhensigtsmæssig afføring og / eller vandladning) og kun i kombination med adfærdsmæssige modifikationsteknikker.

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

n.v. organon - mometasonfuroat - inhalationspulver - 200 mikrogram/dosis

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - mometasonfuroat - inhalationspulver - 400 mikrogram/dosis

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - mometasonfuroat - inhalationspulver - 400 mikrogram/dosis

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - mometasonfuroat - inhalationspulver - 400 mikrogram/dosis